<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Fetal tachyarrhythmia may result in low cardiac output and <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Consequently, antiarrhythmic treatment is offered in most affected pregnancies </plain></SENT>
<SENT sid="2" pm="."><plain>We compared 3 drugs commonly used to control <z:hpo ids='HP_0004755'>supraventricular tachycardia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e>) and <z:hpo ids='HP_0004749'>atrial flutter</z:hpo> (AF) </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: We reviewed 159 consecutive referrals with fetal <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> (n=114) and AF (n=45) </plain></SENT>
<SENT sid="4" pm="."><plain>Of these, 75 fetuses with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> and 36 with AF were treated nonrandomly with transplacental flecainide (n=35), sotalol (n=52), or digoxin (n=24) as a first-line agent </plain></SENT>
<SENT sid="5" pm="."><plain>Prenatal treatment failure was associated with an incessant versus intermittent <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> pattern (n=85; hazard ratio [HR]=3.1; P&lt;0.001) and, for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e>, with fetal <z:hpo ids='HP_0000969'>hydrops</z:hpo> (n=28; HR=1.8; P=0.04) </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0004749'>Atrial flutter</z:hpo> had a lower rate of conversion to sinus rhythm before delivery than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> (HR=2.0; P=0.005) </plain></SENT>
<SENT sid="7" pm="."><plain>Cardioversion at 5 and 10 days occurred in 50% and 63% of treated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> cases, respectively, but in only 25% and 41% of treated AF cases </plain></SENT>
<SENT sid="8" pm="."><plain>Sotalol was associated with higher rates of prenatal AF termination than digoxin (HR=5.4; P=0.05) or flecainide (HR=7.4; P=0.03) </plain></SENT>
<SENT sid="9" pm="."><plain>If incessant AF/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> persisted to day 5 (n=45), median ventricular rates declined more with flecainide (-22%) and digoxin (-13%) than with sotalol (-5%; P&lt;0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>Flecainide (HR=2.1; P=0.02) and digoxin (HR=2.9; P=0.01) were also associated with a higher rate of conversion of fetal <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> to a <z:mpath ids='MPATH_458'>normal</z:mpath> rhythm over time </plain></SENT>
<SENT sid="11" pm="."><plain>No serious drug-related adverse events were observed, but <z:hpo ids='HP_0011675'>arrhythmia</z:hpo>-related mortality was 5% </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: Flecainide and digoxin were superior to sotalol in converting <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> to a <z:mpath ids='MPATH_458'>normal</z:mpath> rhythm and in slowing both AF and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> to better-tolerated ventricular rates and therefore might be considered first to treat significant fetal tachyarrhythmia </plain></SENT>
</text></document>